Pancreatic cancer associated with obesity and diabetes: An alternative approach for its targeting

Ramesh Pothuraju, Satyanarayana Rachagani, Wade M. Junker, Sanjib Chaudhary, Saraswathi Viswanathan, Sukwinder Kaur, Surinder Kumar Batra

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Background: Pancreatic cancer (PC) is among foremost causes of cancer related deaths worldwide due to generic symptoms, lack of effective screening strategies and resistance to chemo- and radiotherapies. The risk factors associated with PC include several metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (T2DM). Studies have shown that obesity and T2DM are associated with PC pathogenesis; however, their role in PC initiation and development remains obscure. Main body: Several biochemical and physiological factors associated with obesity and/or T2DM including adipokines, inflammatory mediators, and altered microbiome are involved in PC progression and metastasis albeit by different molecular mechanisms. Deep understanding of these factors and causal relationship between factors and altered signaling pathways will facilitate deconvolution of disease complexity as well as lead to development of novel therapies. In the present review, we focuses on the interplay between adipocytokines, gut microbiota, adrenomedullin, hyaluronan, vanin and matrix metalloproteinase affected by metabolic alteration and pancreatic tumor progression. Conclusions: Metabolic diseases, such as obesity and T2DM, contribute PC development through altered metabolic pathways. Delineating key players in oncogenic development in pancreas due to metabolic disorder could be a beneficial strategy to combat cancers associated with metabolic diseases in particular, PC.

Original languageEnglish (US)
Article number319
JournalJournal of Experimental and Clinical Cancer Research
Volume37
Issue number1
DOIs
StatePublished - Dec 19 2018

Fingerprint

Pancreatic Neoplasms
Obesity
Type 2 Diabetes Mellitus
Adipokines
Metabolic Diseases
Adrenomedullin
Neoplasms
Microbiota
Hyaluronic Acid
Metabolic Networks and Pathways
Matrix Metalloproteinases
Insulin Resistance
Pancreas
Radiotherapy
Neoplasm Metastasis
Drug Therapy

Keywords

  • Adiponectin
  • Diabetes
  • Gut microbiota
  • Inflammation
  • Insulin resistance
  • Leptin
  • Obesity
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{c23cdf72f1eb470f8e6032f085c07a1a,
title = "Pancreatic cancer associated with obesity and diabetes: An alternative approach for its targeting",
abstract = "Background: Pancreatic cancer (PC) is among foremost causes of cancer related deaths worldwide due to generic symptoms, lack of effective screening strategies and resistance to chemo- and radiotherapies. The risk factors associated with PC include several metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (T2DM). Studies have shown that obesity and T2DM are associated with PC pathogenesis; however, their role in PC initiation and development remains obscure. Main body: Several biochemical and physiological factors associated with obesity and/or T2DM including adipokines, inflammatory mediators, and altered microbiome are involved in PC progression and metastasis albeit by different molecular mechanisms. Deep understanding of these factors and causal relationship between factors and altered signaling pathways will facilitate deconvolution of disease complexity as well as lead to development of novel therapies. In the present review, we focuses on the interplay between adipocytokines, gut microbiota, adrenomedullin, hyaluronan, vanin and matrix metalloproteinase affected by metabolic alteration and pancreatic tumor progression. Conclusions: Metabolic diseases, such as obesity and T2DM, contribute PC development through altered metabolic pathways. Delineating key players in oncogenic development in pancreas due to metabolic disorder could be a beneficial strategy to combat cancers associated with metabolic diseases in particular, PC.",
keywords = "Adiponectin, Diabetes, Gut microbiota, Inflammation, Insulin resistance, Leptin, Obesity, Pancreatic cancer",
author = "Ramesh Pothuraju and Satyanarayana Rachagani and Junker, {Wade M.} and Sanjib Chaudhary and Saraswathi Viswanathan and Sukwinder Kaur and Batra, {Surinder Kumar}",
year = "2018",
month = "12",
day = "19",
doi = "10.1186/s13046-018-0963-4",
language = "English (US)",
volume = "37",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Pancreatic cancer associated with obesity and diabetes

T2 - An alternative approach for its targeting

AU - Pothuraju, Ramesh

AU - Rachagani, Satyanarayana

AU - Junker, Wade M.

AU - Chaudhary, Sanjib

AU - Viswanathan, Saraswathi

AU - Kaur, Sukwinder

AU - Batra, Surinder Kumar

PY - 2018/12/19

Y1 - 2018/12/19

N2 - Background: Pancreatic cancer (PC) is among foremost causes of cancer related deaths worldwide due to generic symptoms, lack of effective screening strategies and resistance to chemo- and radiotherapies. The risk factors associated with PC include several metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (T2DM). Studies have shown that obesity and T2DM are associated with PC pathogenesis; however, their role in PC initiation and development remains obscure. Main body: Several biochemical and physiological factors associated with obesity and/or T2DM including adipokines, inflammatory mediators, and altered microbiome are involved in PC progression and metastasis albeit by different molecular mechanisms. Deep understanding of these factors and causal relationship between factors and altered signaling pathways will facilitate deconvolution of disease complexity as well as lead to development of novel therapies. In the present review, we focuses on the interplay between adipocytokines, gut microbiota, adrenomedullin, hyaluronan, vanin and matrix metalloproteinase affected by metabolic alteration and pancreatic tumor progression. Conclusions: Metabolic diseases, such as obesity and T2DM, contribute PC development through altered metabolic pathways. Delineating key players in oncogenic development in pancreas due to metabolic disorder could be a beneficial strategy to combat cancers associated with metabolic diseases in particular, PC.

AB - Background: Pancreatic cancer (PC) is among foremost causes of cancer related deaths worldwide due to generic symptoms, lack of effective screening strategies and resistance to chemo- and radiotherapies. The risk factors associated with PC include several metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (T2DM). Studies have shown that obesity and T2DM are associated with PC pathogenesis; however, their role in PC initiation and development remains obscure. Main body: Several biochemical and physiological factors associated with obesity and/or T2DM including adipokines, inflammatory mediators, and altered microbiome are involved in PC progression and metastasis albeit by different molecular mechanisms. Deep understanding of these factors and causal relationship between factors and altered signaling pathways will facilitate deconvolution of disease complexity as well as lead to development of novel therapies. In the present review, we focuses on the interplay between adipocytokines, gut microbiota, adrenomedullin, hyaluronan, vanin and matrix metalloproteinase affected by metabolic alteration and pancreatic tumor progression. Conclusions: Metabolic diseases, such as obesity and T2DM, contribute PC development through altered metabolic pathways. Delineating key players in oncogenic development in pancreas due to metabolic disorder could be a beneficial strategy to combat cancers associated with metabolic diseases in particular, PC.

KW - Adiponectin

KW - Diabetes

KW - Gut microbiota

KW - Inflammation

KW - Insulin resistance

KW - Leptin

KW - Obesity

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85058891058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058891058&partnerID=8YFLogxK

U2 - 10.1186/s13046-018-0963-4

DO - 10.1186/s13046-018-0963-4

M3 - Review article

C2 - 30567565

AN - SCOPUS:85058891058

VL - 37

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 319

ER -